ScreenerHero

DBVT DBV Technologies S.A.

NAS · US · Healthcare · Biotechnology · dbv-technologies.com
9.770USD-2.10%Mkt Cap: 614.03M $P/E: —

DBV Technologies S.A., a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products in France. Its product pipeline comprising Viaskin Peanut, an immunotherap…

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$128.08BUSDP/E 29.4
MRNA
Moderna, Inc.
$78.44BUSD
REGN
Regeneron Pharmaceuticals, Inc.
$76.40BUSDP/E 18.4
ARGX
argenx SE
$57.03BUSDP/E 37.3
ARGX
argenx SE
$58.08BUSDP/E 35.4
UCB
UCB SA
$42.24BUSDP/E 18.0
RVMD
Revolution Medicines, Inc.
$43.05BUSD
ONC
BeOne Medicines AG
$41.41BUSDP/E 65.1
RPRX
Royalty Pharma plc
$32.80BUSDP/E 30.2
ALNY
Alnylam Pharmaceuticals, Inc.
$30.03BUSDP/E 37.8
ROIV
Roivant Sciences Ltd.
$25.10BUSD
BNTX
BioNTech SE
$23.93BUSD
GMAB
Genmab A/S
$22.27BUSDP/E 30.7
INCY
Incyte Corporation
$22.99BUSDP/E 14.5
GMAB
Genmab A/S
$22.54BUSDP/E 28.9
INSM
Insmed Incorporated
$22.22BUSD
ASND
Ascendis Pharma A/S
$15.03BUSDP/E 17.5
JAZZ
Jazz Pharmaceuticals plc
$15.01BUSDP/E 15.8
EXEL
Exelixis, Inc.
$14.48BUSDP/E 18.4
SMMT
Summit Therapeutics Inc.
$14.32BUSD

Key Statistics

Company
Market Cap614.03M USD
Enterprise Value423.45M USD
Revenue (TTM)5.04M USD
Gross Profit5.04M USD
Net Income (TTM)-146.95M USD
Revenue/Share0.09 USD
Last Price9.770 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees170
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-20.43
PEG—
EV/EBITDA-2.42
EV/Revenue84.08
P/S124.55
P/B3.68
EPS (TTM)-3.50
EPS (Forward)-0.49
52W Range
9.1903% of range26.18
52W High26.18 USD
52W Low9.190 USD
Profitability
Gross Margin100.00%
Oper. Margin-7228.57%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-87.07%
ROA-62.87%
Growth
Revenue Growth-53.30%
Earnings Growth—
Cash Flow & Leverage
Operating CF-121.18M USD
CapEx (TTM)538.00K USD
FCF Margin-2081.96%
FCF Yield-17.08%
Net Debt-167.20M USD
Net Debt/EBITDA0.96
Balance Sheet
Debt/Equity0.05
Current Ratio3.72
Quick Ratio3.54
Book Value/Sh2.71 USD
Cash/Share2.96 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio—
Ex-Div Date—
Pay Date—
Splits
Last Split1:2
Split DateJun 7, 2024
Analyst Consensus
Rating1.7 (Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)38.78 USD
Upside (mean)+296.9%
Target Range5.721 USD – 54.62 USD
5.721+296.9% to mean54.62
# Analysts7
Ownership
Shares Out.62.85M
Float34.94M
Insiders0.00%
Institutions41.66%
Short Interest
Short Ratio4.7d
Short % Float2.15%
Short % Out.2.15%
Shares Short1.35M
Short (prev mo.)1.63M
Technical
SMA 5013.19 (-25.9%)
SMA 20017.83 (-45.2%)
Beta-0.24
S&P 52W Chg15.78%
Avg Vol (30d)352.66K
Avg Vol (10d)405.87K
Technical Indicators
RSI (14)25.9
MACD-0.8980
MACD Signal-0.7374
MACD Hist.-0.1606
BB Upper13.75 USD
BB Middle11.75 USD
BB Lower9.744 USD
BB Width34.11%
ATR (14)0.6338 USD
Vol Ratio (20d)1.26x